Galactomannan Positivity and Mortality in Non-Neutropenic Invasive Pulmonary Aspergillosis

A retrospective cohort study of 162 patients with proven or probable invasive pulmonary aspergillosis (IPA) admitted between February 2018 and February 2025. The research, authored by DeZhu Tang, investigates the prognostic value of concurrent pretreatment galactomannan positivity in serum and bronchoalveolar lavage fluid for 30-day all-cause mortality.

Use Cases

• Predicting 30-day mortality risk based on concurrent galactomannan positivity status.
• Training survival analysis models using the reported adjusted hazard ratio and patient stratification.
• Developing early risk stratification tools for non-neutropenic IPA patients based on the study's prognostic marker.
• Benchmarking antifungal therapy outcomes against the reported 29.6% overall mortality rate.

Strengths

• Study includes 162 patient records with a clear sample size of 81 patients per comparison group.
• Provides specific mortality rates (45.7% vs. 13.6%) and a statistically significant adjusted hazard ratio (HR = 3.07).
• Uses standardized first-line antifungal therapy (voriconazole) across all patients, reducing treatment variability.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single-center study, which may limit generalizability.

Provenance

Source

figshare

Collection Method

Single-center, retrospective cohort study.

Time Range

February 2018 to February 2025

Freshness

Last updated 2026-05-13 05:35:12; freshness should be verified.